Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Hepatoblastoma × pembrolizumab × Clear all

Phase

Phase 2/3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 9 Squamous Cell Carcinoma of Head and Neck 6 Head and Neck Neoplasms 4 Neoplasm Metastasis 3 Lung Neoplasms 3 Skin Neoplasms 2 Recurrence 2 Cholangiocarcinoma 2 Advanced Solid Tumor 2 Urinary Bladder Neoplasms 1 Squamous NSCLC 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Oropharyngeal Neoplasms 1 Nonsquamous Non-small Cell Lung Cancer 1 Neoplasms, Squamous Cell 1 Neoplasms 1 Mouth Neoplasms 1 Mesothelioma 1 Melanoma 1 Liver Neoplasms 1 Laryngeal Neoplasms 1 Klatskin Tumor 1 Hypopharyngeal Neoplasms 1 Hodgkin Disease 1 Hepatoblastoma 1 Esophageal Squamous Cell Carcinoma 1 Carcinoma, Transitional Cell 1 Carcinoma, Squamous Cell 1 Carcinoma, Merkel Cell 1 Camurati-Engelmann Syndrome 1

Interventions

sintilimab 1 pembrolizumab 1 lenvatinib 1 camrelizumab 1 Sugammadex 1 Immune Checkpoint Inhibitors 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05322187 2022-04-11

sPLENTY-pc

RenJi Hospital

Phase 2/3 Unknown

Gastrointestinal

Liver Neoplasms, Neoplasms, Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡